Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pyrimidinones"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 1001
Tytuł:
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Autorzy:
Puyalto A; Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
Rodríguez-Remírez M; Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
López I; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.
Macaya I; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Guruceaga E; Bioinformatics Platform, Cima Universidad de Navarra, Pamplona, Spain.
Olmedo M; Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.
Vilalta-Lacarra A; Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.
Welch C; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Sandiego S; Department of Oncology, Fundación Instituto Valenciano de Oncología (FIVO), C/Beltrán Báguena 8. 46009, Valencia, Spain.
Vicent S; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Valencia K; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Biochemistry and Genetics, School of Sciences, Universidad de Navarra, Pamplona, Spain.
Calvo A; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Pio R; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Biochemistry and Genetics, School of Sciences, Universidad de Navarra, Pamplona, Spain.
Raez LE; Memorial Cancer Institute, Memorial Healthcare System, Florida Atlantic University (FAU), Pembroke Pines, FL, USA.
Rolfo C; Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York, USA.
Ajona D; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain. .; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain. .; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. .; Department of Biochemistry and Genetics, School of Sciences, Universidad de Navarra, Pamplona, Spain. .
Gil-Bazo I; Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain. .; Program in Solid Tumors, Cancer Division, Cima Universidad de Navarra, CCUN, Av. Pio XII, 55, 31008, Pamplona, Spain. .; Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain. .; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. .; Department of Oncology, Fundación Instituto Valenciano de Oncología (FIVO), C/Beltrán Báguena 8. 46009, Valencia, Spain. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2024 Apr 20; Vol. 23 (1), pp. 78. Date of Electronic Publication: 2024 Apr 20.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Adenocarcinoma*/genetics
Pyridones*
Pyrimidinones*
Mice ; Animals ; Programmed Cell Death 1 Receptor ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism ; Down-Regulation ; Immune Checkpoint Inhibitors/therapeutic use ; B7-H1 Antigen/metabolism ; Disease Models, Animal ; Cell Line, Tumor ; Tumor Microenvironment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.
Autorzy:
Inoue T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Kunimasa K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Tamiya M; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Kawamura T; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Minami T; Department of Respiratory Medicine and Hematology, Hyogo Medical University, Nishinomiya, Japan.; Department of Thoracic Oncology, Hyogo Medical University, Kobe, Japan.
Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Apr; Vol. 15 (11), pp. 929-933. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Case Reports
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Imidazoles*
Oximes*
Pyridones*
Pyrimidinones*
Humans ; Proto-Oncogene Proteins B-raf/genetics ; B7-H1 Antigen/genetics ; Mutation
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Butadienyl Ketene: An Unexplored Intermediate in Organic Synthesis
Autorzy:
Maninderjeet K. Mann
Simranpreet K. Wahan
Nitin Tandon
Gaurav Bhargava
Pokaż więcej
Temat:
ketenes
butadienyl ketene
dienyl ketene
[2+2] cycloaddition
[4+2] cycloaddition
lactams
pyrimidinones
Chemistry
QD1-999
Źródło:
SynOpen, Vol 08, Iss 02, Pp 109-115 (2024)
Opis pliku:
electronic resource
Relacje:
https://doaj.org/toc/2509-9396
Dostęp URL:
https://doaj.org/article/04e0c835d5b64f798d110a80780f906f  Link otwiera się w nowym oknie
Czasopismo naukowe
Szczegóły
Tytuł:
Plasma extracellular vesicle microRNAs reflecting the therapeutic effect of the CBP/β-catenin inhibitor PRI-724 in patients with liver cirrhosis.
Autorzy:
Yoshida M; Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Matsuzaki J; Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan. .
Fujita K; Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Kimura M; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Umezu T; Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Tokuda N; Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Yamaguchi T; Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Kuroda M; Department of Molecular Pathology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Ochiya T; Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Saito Y; Division of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Kimura K; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 15; Vol. 14 (1), pp. 6266. Date of Electronic Publication: 2024 Mar 15.
Typ publikacji:
Journal Article
MeSH Terms:
MicroRNAs*/metabolism
Extracellular Vesicles*/metabolism
Pyrimidinones*
Humans ; beta Catenin/genetics ; beta Catenin/metabolism ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/genetics ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exploration of the Diversity of Vicine and Convicine Derivatives in Faba Bean ( Vicia faba L.) Cultivars: Insights from LC-MS/MS Spectra.
Autorzy:
Sergeant K; Biotechnologies and Environmental Analytics Platform (BEAP), Environmental Research and Innovation Department (ERIN), Luxembourg Institute of Science and Technology (LIST), 5, Rue Bommel, L-4940 Hautcharage, Luxembourg.
Goertz S; NPZ Innovation GmbH, Hohenlieth-Hof 1, 24363 Holtsee, Germany.
Halime S; Biotechnologies and Environmental Analytics Platform (BEAP), Environmental Research and Innovation Department (ERIN), Luxembourg Institute of Science and Technology (LIST), 5, Rue Bommel, L-4940 Hautcharage, Luxembourg.; Université de Reims Champagne-Ardenne, INRAE, RIBP USC 1488, 51100 Reims, France.
Tietgen H; NPZ Innovation GmbH, Hohenlieth-Hof 1, 24363 Holtsee, Germany.
Heidt H; Institut fir Biologësch Landwirtschaft an Agrarkultur Luxemburg a.s.b.l (IBLA), 1 Wantergaass, L-7664 Medernach, Luxembourg.
Minestrini M; Biotechnologies and Environmental Analytics Platform (BEAP), Environmental Research and Innovation Department (ERIN), Luxembourg Institute of Science and Technology (LIST), 5, Rue Bommel, L-4940 Hautcharage, Luxembourg.; Louvain Institute of Biomolecular Science and Technology (LIBST), UCLouvain, Croix du 11 Sud 4-5/L7.07.03, B-1348 Louvain-la-Neuve, Belgium.
Jacquard C; Université de Reims Champagne-Ardenne, INRAE, RIBP USC 1488, 51100 Reims, France.
Zimmer S; Institut fir Biologësch Landwirtschaft an Agrarkultur Luxemburg a.s.b.l (IBLA), 1 Wantergaass, L-7664 Medernach, Luxembourg.
Renaut J; Biotechnologies and Environmental Analytics Platform (BEAP), Environmental Research and Innovation Department (ERIN), Luxembourg Institute of Science and Technology (LIST), 5, Rue Bommel, L-4940 Hautcharage, Luxembourg.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2024 Feb 29; Vol. 29 (5). Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Vicia faba*/chemistry
Fabaceae*
Alkaloids*
Glucosides*
Pyrimidinones*
Uridine/*analogs & derivatives
Liquid Chromatography-Mass Spectrometry ; Chromatography, Liquid ; Tandem Mass Spectrometry ; Plant Breeding
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage.
Autorzy:
Wu T; School of Life Science, University of Science & Technology of China, Hefei, 230027, Anhui, China.; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650201, China.
Liu W; The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China.
Chen H; Key Laboratory of Molecule Synthesis and Function Discovery (Fujian Province University), College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, China.
Hou L; Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Ren W; School of Life Science, University of Science & Technology of China, Hefei, 230027, Anhui, China.; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650201, China.
Zhang L; Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China.
Hu J; The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China. .
Chen H; Key Laboratory of Molecule Synthesis and Function Discovery (Fujian Province University), College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, China. .
Chen C; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, 650201, China. .; The Third Affiliated Hospital, Kunming Medical University, Kunming, 650118, China. .; Academy of Biomedical Engineering, Kunming Medical University, Kunming, 650500, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 18; Vol. 14 (1), pp. 4008. Date of Electronic Publication: 2024 Feb 18.
Typ publikacji:
Journal Article
MeSH Terms:
Triple Negative Breast Neoplasms*/genetics
Pyrimidinones*
Triazines*
Humans ; Reactive Oxygen Species/metabolism ; Cell Proliferation ; Cell Line, Tumor ; Apoptosis ; DNA Damage
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Global repair is the primary nucleotide excision repair subpathway for the removal of pyrimidine-pyrimidone (6-4) damage from the Arabidopsis genome.
Autorzy:
Kaya S; Molecular Biology, Genetics and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey.
Erdogan DE; Department of Molecular Biology and Genetics, College of Sciences, Koc University, Istanbul, Turkey.
Sancar A; Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC, 27599, USA.
Adebali O; Molecular Biology, Genetics and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey. .
Oztas O; Department of Molecular Biology and Genetics, College of Sciences, Koc University, Istanbul, Turkey. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 08; Vol. 14 (1), pp. 3308. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
DNA Repair*
Arabidopsis*/genetics
Pyrimidinones ; Excision Repair ; Pyrimidine Dimers ; DNA Damage ; Receptors, Antigen, T-Cell/genetics ; Ultraviolet Rays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
Autorzy:
van Tilburg CM; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Kilburn LB; Children's National Hospital, Washington, DC, USA.
Perreault S; CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada.
Schmidt R; Institute of Biostatistics and Clinical Research, Münster, Germany.
Azizi AA; Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Cruz-Martínez O; Neuro-oncology Unit, Pediatric Cancer Center, Hospital Sant Joan de Déu, Barcelona, Spain.
Zápotocký M; Department of Paediatric Haematology and Oncology, Charles University, Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Scheinemann K; Division of Oncology-Hematology, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.; Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.; Department of Pediatrics, McMaster Children's Hospital and McMaster University, Hamilton, Canada.
Meeteren AYNS; Department of Neuro-oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Sehested A; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
Opocher E; Pediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University Hospital, Padua, Italy.
Driever PH; German HIT-LOGGIC-Registry for LGG in Children and Adolescents, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Avula S; Department of Radiology, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK.
Ziegler DS; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.; Lowy Cancer Research Centre, Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia.; School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.
Capper D; Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.; DKTK Partner Site, Berlin, Germany.
Koch A; Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sahm F; Department of Neuropathology, German Cancer Research Center (DKFZ), University Hospital Heidelberg and CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
Qiu J; Day One Biopharmaceuticals, Brisbane, CA, USA.
Tsao LP; Day One Biopharmaceuticals, Brisbane, CA, USA.
Blackman SC; Day One Biopharmaceuticals, Brisbane, CA, USA.
Manley P; Day One Biopharmaceuticals, Brisbane, CA, USA.
Milde T; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Witt R; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), Heidelberg, Germany.
Jones DTW; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Division of Pediatric Glioma Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hargrave D; UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children, London, UK.
Witt O; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. .; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. .; Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany. .; German Cancer Consortium (DKTK), Heidelberg, Germany. .; National Center for Tumor Diseases (NCT), Heidelberg, Germany. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jan 30; Vol. 24 (1), pp. 147. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Fireflies*/metabolism
Glioma*/drug therapy
Glioma*/genetics
Glioma*/metabolism
Animals ; Child ; Humans ; Young Adult ; Proto-Oncogene Proteins B-raf ; Treatment Outcome ; Mutation ; Mitogen-Activated Protein Kinases ; Oximes ; Pyridones ; Pyrimidinones/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
Autorzy:
Kawahara N; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan. .
Kawaguchi R; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Yamamoto K; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Nishikawa K; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Matsuoka M; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Maehana T; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Fukui Y; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Yamanaka S; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Sugimoto S; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Iwai K; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Yamada Y; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Kurakami H; Institute for Clinical and Translational Science, Nara Medical University, Kashihara, 634-8522, Japan.
Hirata T; Institute for Clinical and Translational Science, Nara Medical University, Kashihara, 634-8522, Japan.
Takashima R; Institute for Clinical and Translational Science, Nara Medical University, Kashihara, 634-8522, Japan.
Suzuki S; Institute for Clinical and Translational Science, Nara Medical University, Kashihara, 634-8522, Japan.
Asada K; Institute for Clinical and Translational Science, Nara Medical University, Kashihara, 634-8522, Japan.
Kasahara M; Institute for Clinical and Translational Science, Nara Medical University, Kashihara, 634-8522, Japan.
Kimura F; Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, 634-8522, Japan.
Pokaż więcej
Źródło:
Trials [Trials] 2024 Jan 19; Vol. 25 (1), pp. 68. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Leiomyoma*/drug therapy
Leiomyoma*/surgery
Phenylurea Compounds*/therapeutic use
Pyrimidinones*/therapeutic use
Uterine Neoplasms*/drug therapy
Uterine Neoplasms*/surgery
Adult ; Female ; Humans ; Young Adult ; Estradiol/metabolism ; Gonadotropin-Releasing Hormone ; Hormone Antagonists ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Short-term autophagy inhibition by autophinib or SAR405 does not alter the effect of cisplatin on ATP production in prostate cancer cells.
Autorzy:
Kratochvilova M
Stepka P
Raudenska M
Balvan J
Richtera L
Cernei N
Skopalova DS
Zitka O
Filipensky P
Babula P
Masarik M
Pokaż więcej
Źródło:
Bratislavske lekarske listy [Bratisl Lek Listy] 2024; Vol. 124 (2), pp. 84-91.
Typ publikacji:
Journal Article
MeSH Terms:
Cisplatin*/pharmacology
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/pathology
Pyrazoles*
Pyridines*
Pyrimidines*
Pyrimidinones*
Male ; Humans ; Autophagy ; Cell Line, Tumor ; Amino Acids/pharmacology ; Amino Acids/metabolism ; Adenosine Triphosphate/pharmacology ; Arginine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Iron Oxide Nanoparticles with Supramolecular Ureido-Pyrimidinone Coating for Antimicrobial Peptide Delivery.
Autorzy:
Turrina C; Chair of Bioseparation Engineering, School of Engineering and Design, Technical University of Munich, Boltzmannstr. 15, 85748 Garching, Germany.
Cookman J; Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Castletroy, Ireland.
Bellan R; Department of Biomedical Engineering, Institute for Complex Molecular Systems, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands.
Song J; Department of Biomedical Engineering, Institute for Complex Molecular Systems, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands.
Paar M; Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz, Austria.
Dankers PYW; Department of Biomedical Engineering, Institute for Complex Molecular Systems, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands.
Berensmeier S; Chair of Bioseparation Engineering, School of Engineering and Design, Technical University of Munich, Boltzmannstr. 15, 85748 Garching, Germany.
Schwaminger SP; Chair of Bioseparation Engineering, School of Engineering and Design, Technical University of Munich, Boltzmannstr. 15, 85748 Garching, Germany.; Division of Medicinal Chemistry, Otto Loewi Research Center, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz, Austria.; BioTechMed-Graz, Mozartgasse 12, 8010 Graz, Austria.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Sep 27; Vol. 24 (19). Date of Electronic Publication: 2023 Sep 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antimicrobial Peptides*
Anti-Infective Agents*/pharmacology
Animals ; Humans ; Pyrimidinones/chemistry ; Escherichia coli ; Drug Carriers ; Magnetic Iron Oxide Nanoparticles ; Ions ; Mammals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants.
Autorzy:
Scaini MC; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Piccin L; Melanoma Unit, Oncology 2 Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Bassani D; Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padua, Italy.
Scapinello A; Anatomy and Pathological Histology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Pellegrini S; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Poggiana C; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Catoni C; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Tonello D; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Pigozzo J; Melanoma Unit, Oncology 2 Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Dall'Olmo L; Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, 35128 Padua, Italy.
Rosato A; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, 35128 Padua, Italy.
Moro S; Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padua, Italy.
Chiarion-Sileni V; Melanoma Unit, Oncology 2 Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Menin C; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 31; Vol. 24 (15). Date of Electronic Publication: 2023 Jul 31.
Typ publikacji:
Journal Article
MeSH Terms:
Melanoma*/drug therapy
Melanoma*/genetics
Melanoma*/pathology
Skin Neoplasms*/pathology
Male ; Humans ; Proto-Oncogene Proteins B-raf/genetics ; Imidazoles/pharmacology ; Imidazoles/therapeutic use ; Oximes/pharmacology ; Oximes/therapeutic use ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
Autorzy:
Zhong J; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Sun W; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Hu T; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wang C; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yan W; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Luo Z; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Liu X; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xu Y; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Chen Y; Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 May; Vol. 12 (10), pp. 11475-11482. Date of Electronic Publication: 2023 Apr 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Skin Neoplasms*/drug therapy
Skin Neoplasms*/genetics
Melanoma*/drug therapy
Melanoma*/genetics
Humans ; Retrospective Studies ; Proto-Oncogene Proteins B-raf/genetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; China ; Adjuvants, Immunologic/therapeutic use ; Mutation ; Pyridones/adverse effects ; Pyrimidinones/adverse effects ; Melanoma, Cutaneous Malignant
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Trametinib-Resistant Melanoma Cells Displaying MITF Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.
Autorzy:
Koziej P; Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.
Kluszczynska K; Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.
Hartman ML; Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.
Czyz M; Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Apr 26; Vol. 24 (9). Date of Electronic Publication: 2023 Apr 26.
Typ publikacji:
Journal Article
MeSH Terms:
Interleukin-8*/genetics
Melanoma*/drug therapy
Melanoma*/genetics
Melanoma*/pathology
Humans ; Pyridones/pharmacology ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use ; Phenotype ; Proto-Oncogene Proteins B-raf/genetics ; Microphthalmia-Associated Transcription Factor/genetics ; Microphthalmia-Associated Transcription Factor/metabolism ; Nerve Tissue Proteins/genetics ; Receptors, Nerve Growth Factor/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Autorzy:
Krebs FS; Computer-Aided Molecular Engineering, Department of Oncology UNIL-CHUV, University of Lausanne, 1015 Lausanne, Switzerland.; Ludwig Institute for Cancer Research, 1005 Lausanne, Switzerland.
Moura B; Service of Medical Oncology, 1700 Fribourg, Switzerland.
Missiaglia E; Department of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.; Molecular Modelling Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.
Aedo-Lopez V; Monash Medical Centre, Clayton, VIC 3168, Australia.
Michielin O; Molecular Modelling Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.; Service of Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.; Centre for Personalized Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.; Swiss Cancer Center Leman, 1005 Lausanne, Switzerland.; Department of Oncology, Hopitaux Universitaire de Genève, 1205 Geneva, Switzerland.
Tsantoulis P; Swiss Cancer Center Leman, 1005 Lausanne, Switzerland.; Department of Oncology, Hopitaux Universitaire de Genève, 1205 Geneva, Switzerland.
Bisig B; Department of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.
Trimech M; Department of Laboratory Medicine and Pathology, Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne University, 1011 Lausanne, Switzerland.
Zoete V; Computer-Aided Molecular Engineering, Department of Oncology UNIL-CHUV, University of Lausanne, 1015 Lausanne, Switzerland.; Ludwig Institute for Cancer Research, 1005 Lausanne, Switzerland.; Molecular Modelling Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.; Swiss Cancer Center Leman, 1005 Lausanne, Switzerland.
Homicsko K; Ludwig Institute for Cancer Research, 1005 Lausanne, Switzerland.; Service of Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.; Centre for Personalized Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.; Swiss Cancer Center Leman, 1005 Lausanne, Switzerland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Feb 24; Vol. 24 (5). Date of Electronic Publication: 2023 Feb 24.
Typ publikacji:
Case Reports
MeSH Terms:
Skin Neoplasms*/genetics
Melanoma*/genetics
Male ; Humans ; Pyridones/therapeutic use ; Pyrimidinones/therapeutic use ; Protein Kinase Inhibitors/pharmacology ; Mitogen-Activated Protein Kinase Kinases/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Mutation ; MAP Kinase Kinase 1/genetics
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 1001

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies